CMU with Thor Medical

Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, is pleased to invite investors and other interested parties to a capital markets update on Monday, November 25, 2024.

Thor Medical’s CEO Jasper Kurth and CFO Brede Ellingsæter will present an updated investor presentation and will be accompanied by representatives from Artbio. Thor Medical has signed a 5-year master supply agreement for Thorium-228 with Artbio. The agreement marks a significant step towards a positive investment decision for Thor Medical’s planned commercial production plant, targeted in Q1 2025.

The event will be held at Carnegie’s premises in Stockholm, Sweden and a live webcast will be available for those who cannot attend in person.

Location: Regeringsgatan 56, 111 56 Stockholm Date & Time: 25 November, 2024, 13:00-15:00 CET

Registration for physical or digital attendance to the capital markets update can be done through the form. Participants who want to arrange one-to-one meetings are asked to send an email to ellen.mioen@carnegie.se.

It will be possible to ask questions both from the audience and via webcast during the presentations.

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical has produced isotopes at its pilot facilities at Herøya, Norway since October 2024, is headquartered in Oslo and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - https://www.thormedical.no.